1.
Blood
; 136(7): 915, 2020 08 13.
Article
in English
| MEDLINE | ID: covidwho-714293
Subject(s)
Antiviral Agents/adverse effects , Coronavirus Infections/pathology , Eryptosis/drug effects , Erythrocytes/drug effects , Lopinavir/adverse effects , Pneumonia, Viral/pathology , Ritonavir/adverse effects , Aged, 80 and over , Antiviral Agents/administration & dosage , Betacoronavirus/drug effects , Betacoronavirus/immunology , Betacoronavirus/pathogenicity , COVID-19 , Coronavirus Infections/diagnostic imaging , Coronavirus Infections/drug therapy , Coronavirus Infections/virology , Drug Combinations , Erythrocytes/pathology , Erythrocytes/virology , Humans , Lopinavir/administration & dosage , Lung/diagnostic imaging , Lung/pathology , Lung/virology , Male , Pandemics , Pneumonia, Viral/diagnostic imaging , Pneumonia, Viral/drug therapy , Pneumonia, Viral/virology , Ritonavir/administration & dosage , SARS-CoV-2 , Tomography, X-Ray Computed
2.
BMJ Case Rep
; 13(7)2020 Jul 07.
Article
in English
| MEDLINE | ID: covidwho-638342
ABSTRACT
We report on a patient with coronavirus disease 2019 (COVID-19) and decompensated cirrhosis who experienced a favourable outcome of severe immune thrombocytopaenic purpura (ITP) after administration of intravenous immunoglobulin and high-dose dexamethasone. The present case suggests that it is reasonable to evoke ITP in case of profound thrombocytopaenia in a patient with COVID-19.